NASDAQ:OKYO OKYO Pharma Q2 2027 Earnings Date & Estimates $1.09 -0.07 (-6.38%) As of 03:58 PM Eastern This is a fair market value price provided by Massive. Learn more. OKYO Pharma is estimated to report Q2 2027 earnings on Wednesday, December 2, 2026. The conference call is scheduled for November 30, 2026 at 2:00 AM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ2 2027Announcement DateDecember 2, 2026Conference Call DateNovember 30, 2026Conference Call2:00 AM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from OKYO Pharma in Q2 2027OKYO Pharma is expected to post earnings of -$0.06 per share. OKYO Pharma last reported on January 30, 2026, posting -$2.2750 per share and missing the -$0.07 consensus estimate.Consensus EstimatesConsensus EPS-$0.06Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$2.2750 (Missed by -$2.2050)Prepare for the Q2 2027 CallEarnings HistoryCompany ProfileQ2 2026 Earnings Report OKYO Pharma Q2 2027 Earnings FAQ When does OKYO Pharma report Q2 2027 earnings? OKYO Pharma (NASDAQ:OKYO) is estimated to report Q2 2027 earnings on Wednesday, December 2, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is OKYO Pharma's Q2 2027 earnings call? OKYO Pharma's Q2 2027 earnings conference call is scheduled for Monday, November 30, 2026 at 2:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for OKYO Pharma? Analysts expect OKYO Pharma to post earnings of -$0.06 per share for Q2 2027. OKYO Pharma Earnings HeadlinesOKYO Pharma to Participate in 2026 Jefferies Global Healthcare Conference in LondonNovember 12, 2026 | globenewswire.comOKYO Pharma to Present at the Stifel 2026 Healthcare ConferenceNovember 5, 2026 | globenewswire.comURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards urges homeowners to check the map and see whether one is near them. Families in Georgia have been forced to sell, entire Ohio neighborhoods are being torn down, and nearly 50,000 Lake Tahoe residents face losing power. Rickards advised the Pentagon and the U.S. intelligence community for decades. He says one man outside Washington can stop it.November 20 at 1:00 AM | Paradigm Press (Ad)Nxera Pharma Enters into Exclusive License, Supply and Commercialization Agreement with Synmosa for QUVIVIQ® (daridorexant) Across Eight Asia-Pacific MarketsOctober 14, 2026 | markets.businessinsider.comOKYO Pharma Begins Phase 3 Trial Of Urcosimod For Neuropathic Corneal PainOctober 6, 2026 | rttnews.comOKYO Pharma Begins Phase 3 NEPTUNE Trial of Urcosimod for Neuropathic Corneal PainOctober 6, 2026 | finance.yahoo.comSee More OKYO Pharma Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like OKYO Pharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OKYO Pharma and other key companies, straight to your email. Email Address About OKYO PharmaOKYO Pharma (NASDAQ:OKYO) Limited is a clinical-stage biopharmaceutical company developing treatments for inflammatory eye diseases and ocular pain. Its research focuses on therapies intended to reduce inflammation and improve symptoms affecting the eye. The company’s lead candidate, urcosimod (OK-101), is a topical eye-drop treatment being developed for dry eye disease. It is designed to act on ChemR23, a receptor involved in regulating inflammation. OKYO has also investigated the candidate’s potential for treating neuropathic corneal pain.View OKYO Pharma ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel ItAirfares Are Up, Flights Are Tight: 3 Airline Stocks Facing a Winter TestHard Drives Were Left for Dead, But Seagate and Western Digital Are SoaringPalo Alto Networks' Q1 Beat Gives Its Stock Rally Another Reason to RunGrand Theft Auto VI Arrives: Why Take-Two Is a Waiting GameWalmart Earnings Change the Narrative as Digital Growth Lifts OutlookWhatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It Upcoming Earnings Hewlett Packard Enterprise (11/23/2026)Medtronic (11/24/2026)Analog Devices (11/24/2026)Autodesk (11/24/2026)Dell Technologies (11/24/2026)Deere & Company (11/25/2026)CrowdStrike (12/1/2026)Marvell Technology (12/1/2026)Bank Of Montreal (12/2/2026)Bank of Nova Scotia (12/2/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.